Pharmaceutical Executive April 22, 2024
Per the agreement, Cellares will integrate and automate some of Bristol Myers Squibb’s CAR T-cell therapies into its Cell Shuttle program.
Bristol Myers Squibb (BMS) and Cellares announced that they have agreed to terms on a $380 million deal to enhance the manufacturing capabilities for chimeric antigen receptor (CAR) T-cell therapies. According to the companies, the deal will see Cellares incorporate a number of BMS’ therapies into its Cell Shuttle platform, which includes fully automated systems. With the deal aiming to improve access to CAR T-cell therapies to patients at a faster rate, BMS will be given exclusive use of Cellares’ smart factories across the United States, Europe, and Japan.1
“The agreement with Cellares is our latest step forward in...
Today's Sponsors
Today's Sponsor